Send to

Choose Destination
J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13022. [Epub ahead of print]

Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.

Author information

Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge, UK.
Institute of Liver Studies, King's College Hospital, London, UK.
Leeds Liver Unit, St James's University Hospital, Leeds, UK.
Scottish Liver Transplant Unit, Royal Infirmary Edinburgh, Edinburgh, Scotland.
Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK.
Newcastle Liver Unit, Freeman Hospital, Newcastle upon Tyne, UK.
Birmingham Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.


Following the introduction of direct-acting antivirals (DAA), there have been reports of declining incidence of hepatitis C (HCV)-related liver disease as a liver transplantation indication. In this study, we assessed the impact of DAA on liver transplant indications in the UK and waiting list outcomes for patients with HCV. We assessed UK adult elective liver transplant registrants between 2006 and 2017. The aetiology of liver disease at registration was reclassified using an accepted hierarchical system and changes were assessed over time and compared before and after the introduction of DAA. Registration UKELD scores and 1-year waiting list outcomes were also compared. The proportion of waiting list patients registered with HCV-related cirrhosis reduced after the introduction of DAA from 10.5% in 2013 to 4.7% in 2016 (P < 0.001). Alcohol-related liver disease (ARLD) was the leading indication for liver transplantation followed by liver cancer (26.1% and 18.4% in 2016, respectively). The proportion of registrations with Hepatocellular carcinoma (HCC) associated with HCV reduced from 46.4% in 2013 to 33.7% in 2016 (P = 0.002). For patients with HCV-related cirrhosis at one year the outcomes of death, transplantation, delisting due to improvement or deterioration and awaiting a graft at 1 year were similar. For patients with HCV-related HCC, the proportion dying at 1 year reduced significantly from 2.9% to 0.0% (P = 0.04). These data demonstrate an association between DAA and reduced listing rates for HCV-related cirrhosis and HCC, but no significant changes in waiting list outcomes other than reduced mortality in the HCC group.


direct-acting antivirals; hepatitis C; liver cirrhosis; liver transplantation


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center